Insmed Incorporated (NASDAQ:INSM) was the recipient of unusually large options trading on Tuesday. Investors bought 1,721 call options on the stock. This is an increase of 1,147% compared to the typical daily volume of 138 call options.

Shares of NASDAQ:INSM traded down $0.23 during midday trading on Wednesday, reaching $22.66. The company’s stock had a trading volume of 69,321 shares, compared to its average volume of 968,935. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -5.43 and a beta of 2.83. The company has a quick ratio of 4.69, a current ratio of 4.82 and a debt-to-equity ratio of 2.48. The stock has a 50 day moving average of $23.99. Insmed has a fifty-two week low of $11.31 and a fifty-two week high of $33.13.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.02). The firm had revenue of $21.90 million during the quarter, compared to the consensus estimate of $19.61 million. As a group, sell-side analysts anticipate that Insmed will post -3.52 EPS for the current year.

In other news, insider Orlov S. Nicole Schaeffer sold 12,000 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $23.24, for a total value of $278,880.00. Following the transaction, the insider now directly owns 36,350 shares of the company’s stock, valued at approximately $844,774. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Lewis sold 400,000 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $26.00, for a total value of $10,400,000.00. Following the completion of the transaction, the chief executive officer now directly owns 480,672 shares in the company, valued at $12,497,472. The disclosure for this sale can be found here. 4.95% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of the stock. FMR LLC increased its holdings in Insmed by 0.6% during the 1st quarter. FMR LLC now owns 11,630,784 shares of the biopharmaceutical company’s stock worth $338,107,000 after purchasing an additional 67,250 shares in the last quarter. Vivo Capital LLC bought a new stake in Insmed during the 1st quarter worth approximately $34,020,000. Emerald Advisers LLC increased its holdings in Insmed by 52.8% during the 1st quarter. Emerald Advisers LLC now owns 921,527 shares of the biopharmaceutical company’s stock worth $26,789,000 after purchasing an additional 318,482 shares in the last quarter. Geode Capital Management LLC increased its holdings in Insmed by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 866,489 shares of the biopharmaceutical company’s stock worth $11,368,000 after purchasing an additional 55,026 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust increased its holdings in Insmed by 64.1% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 841,119 shares of the biopharmaceutical company’s stock worth $24,451,000 after purchasing an additional 328,472 shares in the last quarter.

A number of research analysts have recently issued reports on INSM shares. Zacks Investment Research downgraded H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th. ValuEngine downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. BidaskClub downgraded Ames National from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $52.00 price objective (up from $43.00) on shares of Insmed in a research note on Tuesday, April 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $36.63.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also: What is a capital gain?

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.